Avidity Biosciences Inc

Research Avidity Biosciences Inc (RNA) on Bullrun: market cap USD 233.49M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerRNA
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 233.49M
• Financial periodQ1 2026
• RevenueUSD 19.64M
• Net income-USD 16.63M
• Free cash flow-USD 64.71M

Valuation Snapshot

latest market cap is USD 233.49M.

About Avidity Biosciences Inc

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases.

Frequently asked questions

What is Avidity Biosciences Inc's market cap?

Avidity Biosciences Inc's market capitalization is USD 233.49M.

What does Avidity Biosciences Inc do?

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies.